OMEROS CORP Contract with Customer, Refund Liability, Current
OMEROS CORP (OMER) had Contract with Customer, Refund Liability, Current of $0 as of 2022-12-31, per its 10-K filed 2023-03-13.
Discontinued › Notes
us-gaap:ContractWithCustomerRefundLiabilityCurrent · last filed 2023-03-13
- 2022-12-31: Contract with Customer, Refund Liability, Current $0.00.
- 2021-12-31: Contract with Customer, Refund Liability, Current $2.00M.
- 2021-09-30: Contract with Customer, Refund Liability, Current $2.00M.
- 2021-06-30: Contract with Customer, Refund Liability, Current $1.90M.
| Period end | Contract with Customer, Refund Liability, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-13 |
| 2021-12-31 | $2.00M 10-K · filed 2023-03-13 |
| 2021-09-30 | $2.00M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.90M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.50M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.20M 10-K · filed 2022-03-01 |
| 2020-09-30 | $8.70M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.10M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $4.10M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.60M 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.50M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $2.10M 10-Q · filed 2019-08-08 |
| 2018-12-31 | $400.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |